1

Dacomitinib in NSCLC: a positive trial with little clinical impact

Year:
2018
Language:
english
File:
PDF, 32 KB
english, 2018
4

Tumor Mutation Burden—From Hopes to Doubts

Year:
2019
Language:
english
File:
PDF, 125 KB
english, 2019
18

LUX-Lung 7: is there enough data for a final conclusion?

Year:
2016
Language:
english
File:
PDF, 37 KB
english, 2016
19

Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?

Year:
2017
Language:
english
File:
PDF, 44 KB
english, 2017
20

Rushing will not help to choose the best combination

Year:
2017
Language:
english
File:
PDF, 51 KB
english, 2017
37

Statistical and Clinical Significance in the TERRA Study

Year:
2018
Language:
english
File:
PDF, 428 KB
english, 2018
39

SABR versus conventional fractionation regimens in NSCLC

Year:
2019
Language:
english
File:
PDF, 32 KB
english, 2019
42

New emerging targets in cancer immunotherapy: the role of TIM3

Year:
2019
Language:
english
File:
PDF, 416 KB
english, 2019
46

Measuring tumor mutation burden in cell-free DNA: advantages and limits

Year:
2019
Language:
english
File:
PDF, 128 KB
english, 2019
49

Tumor Mutation Burden—From Doubts to Concerns—In Reply

Year:
2019
Language:
english
File:
PDF, 38 KB
english, 2019